limertinib (diTFA)

• UNSPSC Description:

  limertinib (ASK120067) diTFA is a potent and orally active inhibitor of EGFRT790M (IC50: 0.3 nM) with selectivity over EGFRWT (IC50: 6.0 nM). limertinib diTFA is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC)[1].

• Target Antigen:

  EGFR

• Type:

  Reference compound

• Related Pathways:

  JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

• Field of Research:

  cancer

• Assay Protocol:

  https://www.medchemexpress.com/limertinib-ditfa.html

• Smiles:

  O=C(NC1=CC(NC2=NC=C(C(NC3=CC4=C(C=CC=C4)C=C3)=N2)Cl)=C(C=C1N(CCN(C)C)C)OC)C=C.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O

• Molecular Weight:

  774.11

• References & Citations:

  [1]Tao Zhang, et al. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer. 2020 May 13;19(1):90.

• Shipping Conditions:

  Room Temperature